ArchiMed acquires remote monitoring company ActiGraph in all-equity deal

ArchiMed made the investment from MED II, its small-cap growth fund that closed on €315 million in 2017.

ArchiMed acquired ActiGraph, which provides wearable, remote monitoring of mobility and sleep for drug trials. ArchiMed is buying 75 percent of ActiGraph in an all-equity deal, with company management retaining 10 percent of the company and other shareholder holding 15 percent. ArchiMed made the investment from MED II, its small-cap growth fund that closed on €315 million in 2017.

Press Release

Private equity healthcare specialist, ArchiMed has acquired ActiGraph, a pioneering developer of wearable, remote monitoring technology for academic studies and drug trials. ActiGraph’s mobility and sleep tracking hardware, software and analysis solutions are the most widely used research-grade monitoring systems for activity in the world. ActiGraph’s monitoring devices resemble watches and can be worn on the wrist, waist ankle or thigh. ActiGraph’s revenues are growing 30 percent annually.

In the all-equity deal, ArchiMed is acquiring 75 percent of ActiGraph from historic shareholders, including management. Management will retain 10 percent of the company with other historic shareholders keeping 15 percent. Financial terms were not disclosed.

Based in Pensacola, Florida and founded in 2004, ActiGraph was originally focused on providing technology for a wide range of academic studies involving the monitoring of sleep and movement. Over the last half decade, enabled by the steady refinement of its technology, ActiGraph has aggressively branched into the fast-growing field of remote activity and sleep monitoring for medical research and drug trials. The relevancy of ActiGraph’s remote monitoring – lower-cost and more scalable than non-remote monitoring of variables like ambulatory pain and sleeping patterns – has come into even greater focus as a result of the Covid-19 crisis.

“ArchiMed has the sector expertise, industry network and financial power we need to optimize growth,” says ActiGraph President and COO, Jeremy Wyatt. “In the highly complex fields of global healthcare technology and drug development, their backing will enhance our supplier relationships, regulatory standing, product delivery capabilities, software services and product offerings.” Wyatt added, “I could not be more proud of our employees who have worked so hard to get us to this stage. Their passion, enthusiasm, and commitment to excellence are unsurpassed.”

“We’ll use our knowledge of the global healthcare industry, and more particularly of the drug research space, to help ActiGraph accelerate product development and expand, organically and through acquisition,” says ArchiMed Partner, Robin Filmer-Wilson. “We want to bring ActiGraph’s unparalleled one-stop monitoring solutions for drug development to new areas of the pharma industry.”

ActiGraph is the fifth cross-border investment by MED II, ArchiMed’s small-cap growth buyout fund, which raised €315 million in 2017. It follows the significant exit achieved by MED I in April, with the sale of Polyplus, and the acquisition of DHG in December by MED Platform I, Archimed’s mid-market buy-and-build fund.

About ArchiMed – www.archimed-group.eu
ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the

Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors. ArchiMed’s international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth through internationalization, product and service range expansion and capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above five billion euros. ArchiMed’s investment capacity currently exceeds one billion euros and is potentially twice this amount when including its strategic investment partners.

About ActiGraph – www.actigraphcorp.com – ActiGraph’s mission is to help people live longer, better lives. ActiGraph does that by providing clients with high resolution, digital data that can be used to explain, influence, and predict human health outcomes. ActiGraph is a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s FDA-cleared wearable activity monitors and robust data management and analytics platform have been used extensively to quantify human movement in academic and population health research for two decades. More recently, ActiGraph technology solutions have been widely adopted by pharmaceutical and life sciences organizations seeking to capture and monitor real-world physical activity, mobility, and sleep behavior for patients enrolled in clinical trials.